User profiles for Christopher E. Brightling
christopher brightlingProfessor Respiratory Medicine, University of Leicester Verified email at leicester.ac.uk Cited by 87199 |
Cluster analysis and clinical asthma phenotypes
…, MA Berry, M Thomas, CE Brightling… - American journal of …, 2008 - atsjournals.org
Rationale: Heterogeneity in asthma expression is multidimensional, including variability in
clinical, physiologic, and pathologic parameters. Classification requires consideration of …
clinical, physiologic, and pathologic parameters. Classification requires consideration of …
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
…, LB Bacharier, ED Bateman, CE Brightling… - American journal of …, 2022 - atsjournals.org
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …
updated evidence-based strategy for asthma management and prevention, which can be …
[HTML][HTML] Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
…, J Breeze, A Briggs, E Bright, CE Brightling… - The Lancet …, 2021 - thelancet.com
Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …
hospitalisation with acute disease is not well understood. The aim of this study was to …
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
RH Green, CE Brightling, S McKenna, B Hargadon… - The Lancet, 2002 - thelancet.com
Background Treatment decisions in asthma are based on assessments of symptoms and
simple measures of lung function, which do not relate closely to underlying eosinophilic airway …
simple measures of lung function, which do not relate closely to underlying eosinophilic airway …
[HTML][HTML] Mepolizumab and exacerbations of refractory eosinophilic asthma
P Haldar, CE Brightling, B Hargadon… - New England journal …, 2009 - Mass Medical Soc
Background Exacerbations of asthma are associated with substantial morbidity and mortality
and with considerable use of health care resources. Preventing exacerbations remains an …
and with considerable use of health care resources. Preventing exacerbations remains an …
[HTML][HTML] Mast-cell infiltration of airway smooth muscle in asthma
CE Brightling, P Bradding, FA Symon… - … England Journal of …, 2002 - Mass Medical Soc
Background Asthma and eosinophilic bronchitis are characterized by similar inflammatory
infiltrates in the submucosa of the lower airway. However, eosinophilic bronchitis differs from …
infiltrates in the submucosa of the lower airway. However, eosinophilic bronchitis differs from …
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines
…, DC Bolser, LP Boulet, SS Braman, CE Brightling… - Chest, 2006 - journal.chestnet.org
Abbreviations: ACE angiotensin-converting enzyme; ACP American College of Physicians;
A/D antihistamine/decongestant; ATS American Thoracic Society; BPC bronchoprovocation …
A/D antihistamine/decongestant; ATS American Thoracic Society; BPC bronchoprovocation …
[HTML][HTML] Tezepelumab in adults and adolescents with severe, uncontrolled asthma
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) are heterogeneous
with respect to inflammation and etiology. Objectives: Investigate biomarker expression …
with respect to inflammation and etiology. Objectives: Investigate biomarker expression …
[HTML][HTML] Evidence of a role of tumor necrosis factor α in refractory asthma
…, RH Green, P Bradding, CE Brightling… - … England Journal of …, 2006 - Mass Medical Soc
Background The development of tumor necrosis factor α (TNF-α) antagonists has made it
feasible to investigate the role of this cytokine in refractory asthma. Methods We measured …
feasible to investigate the role of this cytokine in refractory asthma. Methods We measured …